From marketwatch.com
()
CEO Richard Clark
CEO Richard Clark has been the chief executive officer of Merck & Co since 2005. He is 59 years old. Follow Mr. Clark and Merck & Co in the news and blogs or share your own opinion about the company and its leadership.
BOSTON (MarketWatch) -- Merck & Co. and Bristol-Myers Squibb led drugs stocks higher early Monday, joining the broader market in positive territory. The NYSE Arca Pharmaceutical Index rose 1% to 300.82 and the NYSE Arca Biotechnology Index edged up 0.4% to 895.04. Shares of Merck were up 3% at $34.24, while Bristol-Myers shares gained 4% to rest $23.98.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they...
- Cost restraint helps most drugmakers post higher profits, but ... (search.live.com)
At the American Heart Association meeting today, Merck & Co., Inc. said it is confident in the safety and efficacy profiles of ZETIA® (ezetimibe) and VYTORIN® (ezetimibe/simvastatin), and issued the following comment in response to misinterpretation of results from a small 200-patient imaging study called ARBITER 6.
From centredaily.com
()
- Merck Sees High-Single-Digit EPS Growth Through '13 (news.google.com)
With the Schering-Plough merger done, Merck (MRK) CEO Richard Clark is already mulling who will succeed him in the bosses' chair. A look at Clark's retirement package shows he will receive more than $23 million in cash and benefits.
From feedburner.com
()
- New Jersey R&D sites vital, says Merck CEO (in-pharmatechnologist.com)
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck announced today the completion of patient enrollment in the TRA 2P-TIMI 50 clinical trial, a Phase III, randomized, double-blind, placebo-controlled, multinational study of SCH 530348, the companys investigational antiplatelet protease activated receptor-1 (PAR-1) inhibitor. The study, conducted by the Thrombolysis in Myocardial Infarction (TIMI) Study...
From rss.biospace.com
()
- Merck & Co will Überprüfung der Singulair-Patententscheidung (finanztreff.de)
- Merck & Co will 3,5 Mrd USD bis 2013 einsparen (finanztreff.de)
- Merck & Co Inc-Financial Company Report (pr-inside.com)
The Friends of the Wissahickon said Friday that drug maker Merck & Co. has awarded it $780,656 for the two-year Wissahickon Stormwater Mitigation and Sediment Reduction Project it has undertaken in partnership with the Natural Resources staff of the Fairmount Park Commission. (MRK)
More perspectives...
From bizjournals.com
()
